7524 related articles for article (PubMed ID: 22016836)
21. Proteasome: an emerging target for cancer therapy.
Zavrski I; Jakob C; Schmid P; Krebbel H; Kaiser M; Fleissner C; Rosche M; Possinger K; Sezer O
Anticancer Drugs; 2005 Jun; 16(5):475-81. PubMed ID: 15846112
[TBL] [Abstract][Full Text] [Related]
22. Proteasome inhibition in the treatment of cancer.
Richardson PG; Mitsiades C; Hideshima T; Anderson KC
Cell Cycle; 2005 Feb; 4(2):290-6. PubMed ID: 15655370
[TBL] [Abstract][Full Text] [Related]
23. Bortezomib-mediated downregulation of S-phase kinase protein-2 (SKP2) causes apoptotic cell death in chronic myelogenous leukemia cells.
Iskandarani A; Bhat AA; Siveen KS; Prabhu KS; Kuttikrishnan S; Khan MA; Krishnankutty R; Kulinski M; Nasr RR; Mohammad RM; Uddin S
J Transl Med; 2016 Mar; 14():69. PubMed ID: 26956626
[TBL] [Abstract][Full Text] [Related]
24. Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib.
Cusack JC
Cancer Treat Rev; 2003 May; 29 Suppl 1():21-31. PubMed ID: 12738240
[TBL] [Abstract][Full Text] [Related]
25. Proteasome inhibitor therapy in multiple myeloma.
Chauhan D; Hideshima T; Mitsiades C; Richardson P; Anderson KC
Mol Cancer Ther; 2005 Apr; 4(4):686-92. PubMed ID: 15827343
[TBL] [Abstract][Full Text] [Related]
26. Proteasome as an emerging therapeutic target in cancer.
Zavrski I; Kleeberg L; Kaiser M; Fleissner C; Heider U; Sterz J; Jakob C; Sezer O
Curr Pharm Des; 2007; 13(5):471-85. PubMed ID: 17348844
[TBL] [Abstract][Full Text] [Related]
27. Proteasome inhibition in multiple myeloma: therapeutic implication.
Chauhan D; Hideshima T; Anderson KC
Annu Rev Pharmacol Toxicol; 2005; 45():465-76. PubMed ID: 15822185
[TBL] [Abstract][Full Text] [Related]
28. Targeting the ubiquitin-proteasome pathway in cancer therapy.
Ishii Y; Waxman S; Germain D
Anticancer Agents Med Chem; 2007 May; 7(3):359-65. PubMed ID: 17504161
[TBL] [Abstract][Full Text] [Related]
29. The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.
Thaler S; Thiede G; Hengstler JG; Schad A; Schmidt M; Sleeman JP
Int J Cancer; 2015 Aug; 137(3):686-97. PubMed ID: 25530422
[TBL] [Abstract][Full Text] [Related]
30. BU-32: a novel proteasome inhibitor for breast cancer.
Agyin JK; Santhamma B; Nair HB; Roy SS; Tekmal RR
Breast Cancer Res; 2009; 11(5):R74. PubMed ID: 19821999
[TBL] [Abstract][Full Text] [Related]
31. Targeting the ubiquitin-proteasome pathway in breast cancer.
Cardoso F; Ross JS; Picart MJ; Sotiriou C; Durbecq V
Clin Breast Cancer; 2004 Jun; 5(2):148-57. PubMed ID: 15245620
[TBL] [Abstract][Full Text] [Related]
32. Development of the proteasome inhibitor Velcade (Bortezomib).
Adams J; Kauffman M
Cancer Invest; 2004; 22(2):304-11. PubMed ID: 15199612
[TBL] [Abstract][Full Text] [Related]
33. Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells.
Qin JZ; Ziffra J; Stennett L; Bodner B; Bonish BK; Chaturvedi V; Bennett F; Pollock PM; Trent JM; Hendrix MJ; Rizzo P; Miele L; Nickoloff BJ
Cancer Res; 2005 Jul; 65(14):6282-93. PubMed ID: 16024630
[TBL] [Abstract][Full Text] [Related]
34. Proteasome inhibitors in cancer therapy.
Testa U
Curr Drug Targets; 2009 Oct; 10(10):968-81. PubMed ID: 19548862
[TBL] [Abstract][Full Text] [Related]
35. Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials.
Potts BC; Albitar MX; Anderson KC; Baritaki S; Berkers C; Bonavida B; Chandra J; Chauhan D; Cusack JC; Fenical W; Ghobrial IM; Groll M; Jensen PR; Lam KS; Lloyd GK; McBride W; McConkey DJ; Miller CP; Neuteboom ST; Oki Y; Ovaa H; Pajonk F; Richardson PG; Roccaro AM; Sloss CM; Spear MA; Valashi E; Younes A; Palladino MA
Curr Cancer Drug Targets; 2011 Mar; 11(3):254-84. PubMed ID: 21247382
[TBL] [Abstract][Full Text] [Related]
36. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.
Sagawa M; Tabayashi T; Kimura Y; Tomikawa T; Nemoto-Anan T; Watanabe R; Tokuhira M; Ri M; Hashimoto Y; Iida S; Kizaki M
Cancer Sci; 2015 Apr; 106(4):438-46. PubMed ID: 25613668
[TBL] [Abstract][Full Text] [Related]
37. Bortezomib: a novel therapy approved for multiple myeloma.
Richardson PG; Anderson KC
Clin Adv Hematol Oncol; 2003 Oct; 1(10):596-600. PubMed ID: 16258456
[TBL] [Abstract][Full Text] [Related]
38. Intravenous Immunoglobulin G Suppresses Heat Shock Protein (HSP)-70 Expression and Enhances the Activity of HSP90 and Proteasome Inhibitors.
Jones RJ; Singh RK; Shirazi F; Wan J; Wang H; Wang X; Ha MJ; Baljevic M; Kuiatse I; Davis RE; Orlowski RZ
Front Immunol; 2020; 11():1816. PubMed ID: 32903557
[TBL] [Abstract][Full Text] [Related]
39. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies.
Ludwig H; Khayat D; Giaccone G; Facon T
Cancer; 2005 Nov; 104(9):1794-807. PubMed ID: 16178003
[TBL] [Abstract][Full Text] [Related]
40. Mechanistic rationale and clinical evidence for the efficacy of proteasome inhibitors against indolent and mantle cell lymphomas.
Paoluzzi L; O'Connor OA
BioDrugs; 2006; 20(1):13-23. PubMed ID: 16573348
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
